CA3068256A1 - Methods and compositions for chimeric antigen receptor targeting cancer cells - Google Patents

Methods and compositions for chimeric antigen receptor targeting cancer cells Download PDF

Info

Publication number
CA3068256A1
CA3068256A1 CA3068256A CA3068256A CA3068256A1 CA 3068256 A1 CA3068256 A1 CA 3068256A1 CA 3068256 A CA3068256 A CA 3068256A CA 3068256 A CA3068256 A CA 3068256A CA 3068256 A1 CA3068256 A1 CA 3068256A1
Authority
CA
Canada
Prior art keywords
cell
subject
car
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3068256A
Other languages
English (en)
French (fr)
Inventor
Gianpietro Dotti
Soldano Ferrone
Hongwei Du
Xinhui Wang
Cristina FERRONE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
General Hospital Corp
Original Assignee
University of North Carolina at Chapel Hill
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, General Hospital Corp filed Critical University of North Carolina at Chapel Hill
Publication of CA3068256A1 publication Critical patent/CA3068256A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CA3068256A 2017-06-21 2018-06-19 Methods and compositions for chimeric antigen receptor targeting cancer cells Pending CA3068256A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523105P 2017-06-21 2017-06-21
US62/523,105 2017-06-21
PCT/US2018/038289 WO2018236870A2 (en) 2017-06-21 2018-06-19 METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS WITH A CHIMERIC ANTIGENIC RECEPTOR

Publications (1)

Publication Number Publication Date
CA3068256A1 true CA3068256A1 (en) 2018-12-27

Family

ID=64691428

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3068256A Pending CA3068256A1 (en) 2017-06-21 2018-06-19 Methods and compositions for chimeric antigen receptor targeting cancer cells

Country Status (10)

Country Link
US (3) US10233226B2 (https=)
EP (2) EP4548927A3 (https=)
JP (1) JP7352473B2 (https=)
CN (1) CN111386347B (https=)
AU (2) AU2018289428B2 (https=)
CA (1) CA3068256A1 (https=)
DK (1) DK3642344T3 (https=)
ES (1) ES3014942T3 (https=)
FI (1) FI3642344T3 (https=)
WO (1) WO2018236870A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10233226B2 (en) * 2017-06-21 2019-03-19 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
FI3920939T3 (fi) * 2019-02-08 2025-01-03 Biontech Cell & Gene Therapies Gmbh Kimeerisiä anigeenireseptori-modifioituja soluja hoitamaan CLDN6-ekspressoivia syöpiä
CN109880804B (zh) * 2019-03-06 2022-07-15 徐州医科大学 一种靶向b7h3的car-t细胞的制备方法及应用
CN109929039A (zh) * 2019-03-28 2019-06-25 郑州大学第一附属医院 基于cd276抗体的嵌合抗原受体、慢病毒表达载体及其应用
CN112390892B (zh) * 2019-08-14 2024-01-12 博源润生医药（杭州）有限公司 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞
AU2020387401A1 (en) * 2019-11-18 2022-05-26 Board Of Regents, The University Of Texas System Anti-B7-H3 monoclonal antibody and methods of use thereof
AU2021224883A1 (en) * 2020-02-20 2022-09-29 Invenra Inc. Bispecific GD2 and B7H2 binding molecules and methods of use
US20230174653A1 (en) * 2020-04-06 2023-06-08 St. Jude Children's Research Hospital, Inc. B7-h3 chimeric antigen receptors
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
EP4240832A4 (en) * 2020-11-04 2025-01-01 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
CN113527521B (zh) * 2020-12-14 2022-05-31 广州百暨基因科技有限公司 一种抗b7h3嵌合抗原受体及其应用
CN114763381B (zh) * 2021-01-13 2025-01-28 博生吉医药科技(苏州)有限公司 B7-h3嵌合抗原受体修饰的t细胞及其应用
US20240408135A1 (en) * 2021-05-11 2024-12-12 The General Hospital Corporation Methods for treating graft versus host disease
JP2024525727A (ja) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
WO2024112880A1 (en) * 2022-11-23 2024-05-30 The University Of North Carolina At Chapel Hill B7-h3 targeting ligands and methods of use
CN116699136B (zh) * 2023-06-25 2026-03-17 郑州大学 一种用于胰腺导管腺癌早期筛查和诊断的血清蛋白标志物、应用和相应分析方法
CN117025541B (zh) * 2023-08-15 2025-10-17 福建医科大学附属协和医院 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PT2822575T (pt) * 2012-03-03 2020-07-02 Immungene Inc Moléculas de fusão anticorpos-mutante de interferão modificadas
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
WO2015179801A1 (en) * 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
BR112017001183A2 (pt) * 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
EP3193933B1 (en) 2014-09-17 2021-04-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd276 antibodies (b7h3)
EP3285809B1 (en) * 2015-04-20 2019-09-11 eFFECTOR Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
US10562952B2 (en) * 2015-09-10 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 chimeric antigen receptors
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
US10233226B2 (en) * 2017-06-21 2019-03-19 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells

Also Published As

Publication number Publication date
US20200369743A1 (en) 2020-11-26
US20180371053A1 (en) 2018-12-27
CN111386347A (zh) 2020-07-07
JP2020528744A (ja) 2020-10-01
JP7352473B2 (ja) 2023-09-28
EP3642344A4 (en) 2021-03-31
US20190153063A1 (en) 2019-05-23
WO2018236870A2 (en) 2018-12-27
CN111386347B (zh) 2024-08-13
FI3642344T3 (fi) 2025-03-13
US10233226B2 (en) 2019-03-19
AU2018289428B2 (en) 2024-06-27
WO2018236870A3 (en) 2019-02-07
AU2018289428A1 (en) 2020-02-06
EP3642344B1 (en) 2024-12-04
ES3014942T3 (en) 2025-04-28
US10519214B2 (en) 2019-12-31
EP4548927A3 (en) 2025-07-23
EP4548927A2 (en) 2025-05-07
EP3642344A2 (en) 2020-04-29
DK3642344T3 (da) 2025-03-03
AU2024220000A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
US10519214B2 (en) Methods and compositions for chimeric antigen receptor targeting cancer cells
JP7451627B2 (ja) キメラ受容体及びその使用方法
JP7728822B2 (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
CN113597433B (zh) Gprc5d嵌合抗原受体以及表达这些受体的细胞
US9828435B2 (en) Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency
JP2023078394A (ja) Ｃａｒ－ｔ細胞の調節方法
CN113543799A (zh) 靶向dll3的嵌合抗原受体和结合剂
KR20190021203A (ko) Flt3에 대한 키메라 수용체 및 이의 사용 방법
US20250163178A1 (en) Methods and compositions for chimeric antigen receptor targeting cancer cells
WO2023020475A1 (en) Cd40-targetting antibodies and uses thereof
CN115322257B (zh) Bcma靶向抗体、嵌合抗原受体及其应用
WO2017015374A1 (en) Methods and compositions for chimeric antigen receptor targeting the glucose-regulated protein of 94 kda (grp94)
HK40126444A (en) Methods and compositions for chimeric antigen receptor targeting cancer cells
TWI917318B (zh) 靶向ｄｌｌ３的嵌合抗原受體和結合劑
RU2774232C2 (ru) Способы модулирования cart-клеток
HK40126667A (zh) 嵌合抗原和t细胞受体及使用的方法
HK40063038B (zh) 靶向dll3的嵌合抗原受体和结合剂
HK40063038A (en) Dll3 targeting chimeric antigen receptors and binding agents
EA051270B1 (ru) Химерные рецепторы и способы их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230619

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240808

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250206

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250607

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250607

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250613

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250613

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250908

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250926

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20251021

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260126

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260202

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260202